Drug Type Chemical drugs |
Synonyms BLX-0279, BLX0279 |
Target |
Mechanism HDAC6 inhibitors(Histone deacetylase 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Biolexis TherapeuticsStartup |
Active Organization Biolexis TherapeuticsStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | US | Biolexis TherapeuticsStartup | 23 Jan 2024 |
Amyotrophic Lateral Sclerosis | Preclinical | US | Biolexis TherapeuticsStartup | 23 Jan 2024 |
Huntington Disease | Preclinical | US | Biolexis TherapeuticsStartup | 23 Jan 2024 |